Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities

Peptides, Journal Year: 2025, Volume and Issue: 187, P. 171380 - 171380

Published: March 11, 2025

Recent studies with peptide-based incretin herapies have focussed mainly on the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and dual tirzepatide that engages receptors for GLP-1 glucose-dependent insulinotropic polypeptide (GIP). Randomised clinical trials 'real-world' confirmed marked glucose-lowering weight-lowering efficacy of these agents across diverse populations. These include different ethnic groups, young elderly individuals without diabetes and/or overweight or obesity. also protections against development progression cardiovascular renal diseases are additive to benefits conferred by improved control blood glucose body weight. Emerging evidence suggests therapies could additionally ameliorate fatty liver disease, chronic inflammation, sleep apnea possibly degenerative bone disorders cognitive decline. New incretin-based peptide in a long-acting glucagon (LY3324954), GLP-1/glucagon agonists (survodutide, pemvidutide, mazdutide, G49), triple GLP-1/GIP/glucagon (retatrutide, efocipegtrutide), combination amylin analogue cagrilintide (CagriSema), unimolecular GLP-1/amylin (amycretin), GIP antibody agonism (MariTide). The creation multi-targeting synthetic peptides provides opportunities management type 2 obesity as well new therapeutic approaches an expanding list associated co-morbidities. aim review is acquaint reader developments field from 2023 present (February 2025).

Language: Английский

---

Lesson for the clinical nephrologist: glucagon-like peptide-1 receptor agonists (GLP-1 RA) in a patient with obesity and diabetic kidney disease on peritoneal dialysis

Journal of Nephrology, Journal Year: 2025, Volume and Issue: unknown

Published: March 14, 2025

Language: Английский

---

Diabetes Mellitus in Kidney Transplant Recipients: New Horizons in Treatment

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(4), P. 1048 - 1048

Published: Feb. 7, 2025

Diabetes mellitus (DM) in kidney transplant recipients (KTR) is a risk factor for mortality, increases the of infections and, long term, can lead to graft loss due diabetic disease. A preventive approach applied those on waiting list could decrease incidence post-transplant DM (PTDM) by detecting patients at risk, thus allowing strategies minimize probability developing New Onset After Transplant (NODAT). On other hand, modifications immunosuppressive therapy may improve glucose control with KTR. In recent years, two new classes antidiabetic drugs and non-steroidal mineralocorticoid receptor antagonists have demonstrated cardiovascular renal benefits randomized clinical trials where population has not been represented. Because potential benefit expected this population, use glucagon-like peptide-1 agonists (GLP-1RA), sodium-glucose cotransporter 2 inhibitors (SGLT2i) finerenone increasing setting. This review focuses comprehensive pharmacological interventions KTR metabolism disorders. In-depth knowledge area will allow prevention identification adverse effects or drug interactions course DM.

Language: Английский

---

Use of Semaglutide in Diabetes Care Post Renal Transplantation

Current Transplantation Reports, Journal Year: 2025, Volume and Issue: 12(1)

Published: April 2, 2025

Language: Английский

---

Impact of GLP- 1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia

Current Nutrition Reports, Journal Year: 2025, Volume and Issue: 14(1)

Published: April 28, 2025

Language: Английский

---